EPA 2026 Abstract Submission Form

EPA 2026 Annual Conference Abstract Submission Form

Submission Deadline: October 21, 2026
CALL FOR ABSTRACTS

Submission Deadline: October 21, 2026

The Planning Committee for the Eastern Pain Association invites you to submit abstracts for papers to be presented at the upcoming conference at The Fitzpatrick, in New York, NY. Abstracts should describe original research in the field of pain management and physiatry. We welcome residents and fellows to submit abstracts as well.

General Information:

The Eastern Pain Association has reserved time on the program for scientific poster sessions. ePosters will be available for viewing throughout the conference.

Abstracts previously presented or published may not be submitted without modifications, original work must be changed or expanded, resulting in a new abstract.

The Planning Committee will retain the copyright of the published abstracts. Awards will be presented to the top poster presenters.

Submission Information:

Please use the recommended abstract format:

Introduction/Statement of the Problem, Materials and Methods, Results, and Conclusions. The text of your abstract may be up to 300 words.

In 300 words or less, provide an accurate, succinct, and informative representation of the content that will be presented in the paper.
Do not use abbreviations. Type in sentence case. Do not type in all caps.
Do not use the ampersand character (&) unless it is part of a company name.
Proofread for typographical, grammar, and syntax errors.
All abstracts should be submitted electronically as Word documents (with a .doc extension).

Questions for EPA 2026 Abstracts, contact Rosa McKenzie at rosa.mckenzie@scorah.net.

Policy on Commercial Support:

Abstracts must avoid commercialism. Abstracts that constitute promotion and advertising will not be accepted. Statements should not be viewed as or considered representative of any formal stance or position taken on any subject, issue, or product by the EPA 2026 Planning Committee.

Selection Criteria:

Submissions will be reviewed and rated by members of the Scientific Planning Committee who have expertise in the clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, and study design.

Abstract Poster winners will be recognized at the podium during the conference. You will be notified by e-mail of the proposal’s acceptance or rejection by November 1, 2026.

Meeting Registration Guideline for Poster Winners:

Poster winners can register for the meeting and pay the applicable registration fee, as the EPA 2026 Conference will not waive the registration fee. Poster winners are also responsible for all personal expenses (e.g., travel, hotel). You are encouraged to register for the meeting and to reserve hotel accommodations as early as possible to ensure that space is available.

For Registration and Hotel Information, please contact the planning committee at: rosa.mckenzie@scorah.net
Abstract Title

Primary Presenter Name

First NameLast Name
Credentials
Company
City/State
Phone Number
Please enter a valid phone number.Format: (000) 000-0000.
Email
example@example.com

Co-Presenter Name

First NameLast Name
Credentials
Company
City/State
Phone Number
Please enter a valid phone number.Format: (000) 000-0000.
Email
example@example.com

Co-Presenter 2 Name

First NameLast Name
Credentials
Company
City/State
Phone Number
Please enter a valid phone number.Format: (000) 000-0000.
Email
example@example.com

Co-Presenter 3 Name

First NameLast Name
Credentials
Company
City/State
Phone Number
Please enter a valid phone number.Format: (000) 000-0000.
Email
example@example.com

Please attach your abstract which includes: Introduction, Objectives, Materials and Methods, Results, Conclusion, References (Author 1, Author 2, Author 3 et al. Title. Journal Year. Volume: start page-end page), Acknowledgements - please acknowledge any funding source and contributors to the research, Figure and Table Legend. The abstract should be no more than 300 words. References can be separate and will not affect word count. Please attach everything on separate pages, in one file. The uploaded document should be labeled last name.first name of the primary presenter. (ex. Doe.John)

Cancelof
Are you a Fellow or Resident?
Is this Abstract Industry Sponsored?
Disclosures
Do any of the authors of this abstract have any commercial relationships to disclose? - If yes, please complete the Disclosure of Commercial Relationships.
Is any device or drug required FDA approval identified as an important component of your presentation? - If yes, please complete the FDA Disclosure Form.
Signature
Name

First NameLast Name
Date

MonthDayYear
Date
By submitting this abstract, the presenting author certifies the following:

The identical abstract has not been submitted to any other meeting. The material has not been accepted for publication before this submission. All the listed presenters have reviewed this abstract and agree to its submission. Upon acceptance, the presenting author accepts the commitment to possibly present the abstract at the EPA NYC 2026 Conference.
Presenter Biographical Form

This information must be submitted for the Primary Presenter only. Please type the information with your name and credentials exactly as you want them to appear in the published materials.
Name

First NameLast Name
Credentials
Professional Title
Facility
Work Phone Number
Please enter a valid phone number.Format: (000) 000-0000.
Work Fax Number
Please enter a valid phone number.Format: (000) 000-0000.
Mobile Phone Number
Please enter a valid phone number.Format: (000) 000-0000.
Email
example@example.com
Academic Preparation/Institution
Please include Relevant Training and Experience in this Area
Preferred Social Media
Social Handle
Disclosure of Financial Relationships

All authors submitting abstracts for publications are required to disclose any relationships with industry that may direct bearing on relevant subject matter. The primary presenter must disclose any author/presenter who has relevant financial interest or other relationships occurring with the past 12 months with commercial companies or organizations.
Author Name

First NameLast Name

Rows	Company	Company	Company	Company
Board Member/Trustee
Consultant/Advisor
Employee
Investigator
Investment/Stock Options/Shares
Meeting Participant/Lecturer
Owner
Scientific Study/Trial
Other (please specify)

Author Name

First NameLast Name

Rows	Company	Company	Company	Company
Board Member/Trustee
Consultant/Advisor
Employee
Investigator
Investment/Stock Options/Shares
Meeting Participant/Lecturer
Owner
Scientific Study/Trial
Other (please specify)

Author Name

First NameLast Name

Rows	Company	Company	Company	Company
Board Member/Trustee
Consultant/Advisor
Employee
Investigator
Investment/Stock Options/Shares
Meeting Participant/Lecturer
Owner
Scientific Study/Trial
Other (please specify)

Author Name

First NameLast Name

Rows	Company	Company	Company	Company
Board Member/Trustee
Consultant/Advisor
Employee
Investigator
Investment/Stock Options/Shares
Meeting Participant/Lecturer
Owner
Scientific Study/Trial
Other (please specify)

FDA Disclosure

If a device or drug requiring FDA approval is identified as an important component of your presentation, please list the device/drug and indicate the FDA status as either: Approved, Investigational Device/Drug, Not approved for distribution in the United States.
Device/Drug blanks Status blank
Device/Drug blanks Status blank
Device/Drug blanks Status blank
Device/Drug blanks Status blank
Device/Drug blanks Status blank
Device/Drug blanks Status blank
Should be Empty:

EPA 2026 Annual Conference Abstract Submission Form

Disclosures

By submitting this abstract, the presenting author certifies the following:

Presenter Biographical Form

Disclosure of Financial Relationships

FDA Disclosure